Clinical trials: Antitumor Drug
Hepatocellular Carcinoma
Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma
The purpose of this study is to evaluate efficacy, safety, and patient reported outcomes (PRO) of different regimens of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
- Trial name
- TACEforHCC (NCT00493402)
- Testing
- Transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 365 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory)…
- Conditions
- Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT06102902
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 16 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
- Trial name
- NCT06065059
- Testing
- TNG348, Olaparib
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Tango Therapeutics, Inc.
Rectal Cancer
Tecemotide (L-BLP25) in Rectal Cancer
The objective of this mechanistic study is to determine the impact of tecemotide (L-BLP25) administration on the mucinous glycoprotein 1 - (MUC1) specific immune response in subjects with newly diagnosed rectal cancer who are…
- Trial name
- SPRINT (NCT01507103)
- Testing
- Tecemotide (L-BLP25), cyclophosphamide (CPA), Chemoradiotherapy
- Where
- Netherlands
- Volunteers
- 124 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Neoplasms, Melanoma
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
This study has 2 phases. The main aims of Phase 1b are: to check for side effects from modakafusp alfa in adults with locally advanced or metastatic solid tumors.
- Trial name
- NCT04157517
- Testing
- Modakafusp Alfa, Pembrolizumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 45 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Pharmacokinetics, Safety Issues
A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab
The aim of the Clinical study is to evaluate the pharmacokinetic and safety profile of a new formulation of Bevacizumab (Zutrab®, Argentinian origin) when compared to two already marketed formulations of Bevacizumab Avastin®…
- Trial name
- NCT03919448
- Testing
- Bevacizumab
- Where
- Argentina
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Carcinoma, Non-Small Cell-Lung, Lung Neoplasms
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
During Phase 1b portion, there will be a dose-escalation of AV-299 (formerly SCH 900105) in combination with the recommended dose of gefitinib in subjects with NSCLC or advanced solid tumor.
- Conditions
- Carcinoma, Non-Small Cell-Lung, Lung Neoplasms, Lung Cancer, Respiratory Tract Neoplasms
- Trial name
- NCT01039948
- Testing
- AV-299 + gefitinib, Gefitinib
- Where
- 26 sites in Hong Kong, Malaysia and 5 more
- Volunteers
- 203 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Antitumor Drug, Pharmacokinetics
SPH3348 Tablets in a Single-center, Randomized, Open-label, Single-dose, Two-period, Two-sequence Crossover Design Food Effect Study in Healthy Chinese Subjects
The goal of this clinical trial is to evaluate the pharmacokinetic (PK) characteristics of single oral doses of SPH3348 tablets in healthy subjects under fasting and fed conditions, as well as the impact of food on PK.
- Trial name
- NCT06652997
- Testing
- SPH3348
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- West China Second University Hospital
Hepatocellular Carcinoma, Liver Neoplasms
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%.
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms, Sorafenib
- Trial name
- NCT04518852
- Testing
- TACE combined with sorafenib and PD-1 mAb
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or…
- Conditions
- Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular, Liver Diseases
- Trial name
- NCT01009593
- Testing
- ABT-869, Sorafenib
- Where
- 163 sites in United States, Argentina and 27 more
- Volunteers
- 1,035 people
- Sponsor
- Abbott
Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
This phase II trial tests how well atezolizumab works in combination with tiragolumab in treating patients with rare solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts…
- Conditions
- Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
- Trial name
- NCT05715281
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumours
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
The purpose of this study is to determine whether AZD0156 is safe, what is the best dose to give, and how it is processed by the body when given alone or in combination with other agents.
- Trial name
- AToM (NCT02588105)
- Testing
- AZD0156, Olaparib, irinotecan
- Where
- 5 sites in United States, South Korea and 2 more
- Volunteers
- 84 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy
Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints leading to joint destruction, with significant long-term morbidity and mortality.
- Trial name
- RACAT (NCT00405275)
- Testing
- Etanercept, methotrexate, Sulfasalazine
- Where
- 37 sites in United States, Canada
- Volunteers
- 353 people
- Sponsor
- US Department of Veterans Affairs
Antineoplastic Agents
Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?
This study is being conducted by Bassett Healthcare Network in coordination with Bassett Cancer Institute. Patients prescribed oral chemotherapies will be approached to consider consent to this study.
- Trial name
- NCT02468245
- Testing
- weekly telephone follow up, usual care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Bassett Healthcare
Neoplasms, Solid Tumors
ADC-1013 First-in-Human Study
The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or…
- Trial name
- NCT02379741
- Testing
- ADC-1013
- Where
- 5 sites in Denmark, Sweden and 1 more
- Volunteers
- 24 people
- Sponsor
- Alligator Bioscience AB
Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread…
- Conditions
- Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
- Trial name
- NCT07227415
- Testing
- PF-08634404, Ipilimumab, Axitinib
- Where
- 183 sites in United States, Australia and 4 more
- Volunteers
- 224 people
- Sponsor
- Pfizer
Breast Cancer, Locally Advanced Breast Cancer
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
- Conditions
- Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
- Trial name
- OPERA-02 (NCT07085767)
- Testing
- Palazestrant, Ribociclib, Letrozole
- Where
- 200 sites in United States, Australia and 21 more
- Volunteers
- 1,000 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Metastatic Breast Cancer
IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer
Current patient work-up, including conventional imaging and pathological assessment of just one single biopsy, might be insufficient to identify metastatic breast cancer patients, who possibly benefit from first-line…
- Trial name
- IMPACT-MBC (NCT01957332)
- Testing
- Molecular imaging
- Where
- 3 sites in Netherlands
- Volunteers
- 217 people
- Sponsor
- University Medical Center Groningen
Ovarian Cancer, Fallopian Tube Cancer
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of niraparib in Japanese participants with platinum-sensitive, relapsed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who achieved complete…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03759587
- Testing
- Niraparib
- Where
- 27 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Takeda
Neoplasms Malignant
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104
This was a first-in-human, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 as monotherapy or in combination with AK104 in subjects…
- Trial name
- NCT04349969
- Testing
- AK117, AK117+AK104
- Where
- 4 sites in Australia
- Volunteers
- 38 people
- Sponsor
- Akesobio Australia Pty Ltd